1. Home
  2. STAA vs ARQT Comparison

STAA vs ARQT Comparison

Compare STAA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

N/A

Current Price

$22.52

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

N/A

Current Price

$24.53

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STAA
ARQT
Founded
1982
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
3.5B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
STAA
ARQT
Price
$22.52
$24.53
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$22.81
$34.00
AVG Volume (30 Days)
721.2K
1.8M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.79
EPS
0.26
0.03
Revenue
$239,442,000.00
$376,072,000.00
Revenue This Year
$30.82
$34.85
Revenue Next Year
$8.41
$29.39
P/E Ratio
$86.60
$824.50
Revenue Growth
N/A
91.34
52 Week Low
$15.59
$16.68
52 Week High
$35.87
$31.77

Technical Indicators

Market Signals
Indicator
STAA
ARQT
Relative Strength Index (RSI) 41.22 40.14
Support Level $21.72 $22.73
Resistance Level $24.31 $23.87
Average True Range (ATR) 0.94 0.84
MACD 0.04 0.02
Stochastic Oscillator 26.01 17.12

Price Performance

Historical Comparison
STAA
ARQT

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: